Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 May 26;3(2):113-120.
doi: 10.1089/psymed.2024.0033. eCollection 2025 Jun.

Exploring Psychedelics for Unmet Needs in Women's Reproductive Health

Affiliations
Review

Exploring Psychedelics for Unmet Needs in Women's Reproductive Health

Sara Shoar et al. Psychedelic Med (New Rochelle). .

Abstract

Background: In recent years, there has been a resurgence in research exploring the therapeutic potential of psychedelics for treating mental health disorders, coinciding with increasing psychedelic use and changing legal landscapes in the United States and globally. Despite these shifts, there remains a notable gap in understanding related to the safety of psychedelic use during critical stages of the female reproductive cycle, including menstruation, pregnancy, postpartum, breastfeeding, and menopause.

Methods: This narrative mini-review provides a brief summary of recently published articles in this evolving therapeutic landscape and discusses critical public health implications for addressing psychedelic use for women's reproductive health.

Results: Studies have uncovered notable sex differences in users' subjective and physiological experiences of psychedelics. Interactions between psychedelics' mechanisms of action and female hormones suggest opportunities for addressing symptoms of menstruation, sexual dysfunction, chronic pelvic pain, menopause, and postpartum depression (PPD). Women in indigenous communities have traditionally used psychedelics as important components of healing rituals. Yet, potential risks associated with psychedelic use during the reproductive years, specifically during gestation and breastfeeding, underscore the importance of caution and informed decision-making.

Conclusion: While there is therapeutic potential for psychedelics in women's reproductive health issues, comprehensive research pertaining to women is lacking. While rigorous scientific inquiry into the safety, efficacy, and mechanisms of action of psychedelics in women's health is paramount, public health messaging should dispel myths and promote risk reduction strategies. Collaboration with indigenous communities and vulnerable populations can enrich understanding and ensure culturally sensitive approaches. Through enhanced research and collaboration, psychedelics can be explored to potentially address unmet needs and enhance women's well-being across diverse reproductive contexts. Existing guidance fails to focus on recommendations for women, highlighting the need for harm reduction strategies.

Keywords: postpartum depression; pregnancy; psychedelics; reproductive health; women’s health.

PubMed Disclaimer

Similar articles

References

    1. Doblin R. FDA grants breakthrough therapy designation for MDMA-assisted therapy for PTSD, agrees on special protocol assessment for phase 3 trials. MAPS; August 26, 2017. Available from: https://maps.org/news/media/press -release-fda-grants-breakthrough-thera...
    1. Pathways C. COMPASS pathways receives FDA breakthrough therapy designation for psilocybin therapy for treatment-resistant depression. COMPASS Pathways; October 23, 2018. Available from: https://ir.compasspathways.com/news-releases/news-release-details/compas...
    1. Institute U. FDA grants breakthrough therapy designation to Usona Institute’s psilocybin program for major depressive disorder. Usona Institute. November 22, 2019. Available from: https://www.usonainstitute.org/updates/fda-grants-breakthrough-therapy-d...
    1. MindMed. MindMed receives FDA breakthrough therapy designation and announces positive 12-week durability data from phase 2B study of MM120 for generalized anxiety disorder. MindMed. March 7, 2024. Available from: https://ir.mindmed.co/news-events/press-releases/detail/137/mindmed-rece...
    1. Cybin. Cybin receives FDA breakthrough therapy designation for its novel psychedelic molecule CYB003 and announces positive four-month durability data in major depressive disorder. Cybin. March 13, 2024. Available from: https://ir.cybin.com/investors/news/news-details/2024/Cybin-Receives-FDA...

LinkOut - more resources